- Home
- EVE vs BWAY Comparison
EVE vs BWAY Comparison
Compare EVE & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVE
- BWAY
- Stock Information
- Founded
- EVE 2021
- BWAY 2003
- Country
- EVE United States
- BWAY Israel
- Employees
- EVE N/A
- BWAY N/A
- Industry
- EVE Blank Checks
- BWAY Medical/Dental Instruments
- Sector
- EVE Finance
- BWAY Health Care
- Exchange
- EVE Nasdaq
- BWAY Nasdaq
- Market Cap
- EVE 161.5M
- BWAY 159.3M
- IPO Year
- EVE 2021
- BWAY 2019
- Fundamental
- Price
- EVE $11.28
- BWAY $9.84
- Analyst Decision
- EVE
- BWAY Strong Buy
- Analyst Count
- EVE 0
- BWAY 3
- Target Price
- EVE N/A
- BWAY $13.17
- AVG Volume (30 Days)
- EVE 5.0K
- BWAY 88.5K
- Earning Date
- EVE 01-01-0001
- BWAY 11-12-2024
- Dividend Yield
- EVE N/A
- BWAY N/A
- EPS Growth
- EVE 4067.26
- BWAY N/A
- EPS
- EVE 0.24
- BWAY 0.04
- Revenue
- EVE N/A
- BWAY $38,631,000.00
- Revenue This Year
- EVE N/A
- BWAY $378.91
- Revenue Next Year
- EVE N/A
- BWAY $20.27
- P/E Ratio
- EVE $46.20
- BWAY $122.14
- Revenue Growth
- EVE N/A
- BWAY 34.19
- 52 Week Low
- EVE $10.63
- BWAY $4.61
- 52 Week High
- EVE $12.03
- BWAY $10.98
- Technical
- Relative Strength Index (RSI)
- EVE 66.82
- BWAY 51.55
- Support Level
- EVE $11.19
- BWAY $8.96
- Resistance Level
- EVE $11.30
- BWAY $10.27
- Average True Range (ATR)
- EVE 0.04
- BWAY 0.61
- MACD
- EVE 0.00
- BWAY -0.09
- Stochastic Oscillator
- EVE 88.24
- BWAY 50.86
About EVE EVe Mobility Acquisition Corp
EVe Mobility Acquisition Corp is a blank check company.
About BWAY BrainsWay Ltd.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.